The Risk of Pneumonitis From Radiation in Patients With Lung Cancer
Laurie Gaspar, MD, Professor and Chair Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses the risk of pneumonitis from radiation among patients with lung cancer.
Laurie Gaspar, MD, Professor and Chair Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses the risk of pneumonitis from radiation among patients with lung cancer.
Clinical Pearls
Some large cooperative group studies claim that the risk of symptomatic radiation pneumonitis is small -- less than 10%. On an actuarial basis, Gaspar says, about 30-40% of patients experience pneumonitis at 1 year.Gaspar says this larger figure needs to be discussed with patients and physicians need to work on lowering the percentage. Most oncologists also agree that some side effects from radiation are being underestimated, Gaspar says
- Patients need to be more aware of the real risk of pneumonitis from radiation
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
